Concord Biotech Reports Strong Financial Results, Receives 'Buy' Call from MarketsMOJO

Concord Biotech, a midcap pharmaceutical company, has recently announced its financial results for the quarter ending September 2024. The company has received a 'Buy' call from MarketsMOJO, indicating positive growth potential.

In the last three months, Concord Biotech has shown a significant improvement in its financial performance, with a score of 11 compared to -3. This is a result of the company's strong operating cash flow, which has been consistently growing over the past three years. In the last five quarters, the company has also recorded its highest operating profit (PBDIT) and profit before tax (PBT) less other income. This trend is expected to continue in the near future.

Concord Biotech's profit after tax (PAT) has also shown a positive trend, with the highest recorded in the last five quarters. This is a 22.3% increase over the average PAT of the previous four quarters, indicating the company's strong profitability. The earnings per share (EPS) have also been consistently increasing, with the highest recorded in the last five quarters. This shows that the company is creating higher earnings for its shareholders.

In addition, Concord Biotech has a track record of distributing higher dividends to its shareholders, with the highest dividend per share (DPS) recorded in the last five years. The company has also maintained a high dividend payout ratio (DPR) of 30.04% in the last five years, indicating its commitment to sharing profits with its shareholders.

Overall, Concord Biotech's financial results for the quarter ending September 2024 have been positive and reflect the company's strong performance in the pharmaceutical industry. With a 'Buy' call from MarketsMOJO, investors can expect continued growth and profitability from this midcap company.